Biologics in vasculitides: Where do we stand, where do we go from now?

Giulia Pazzola, Francesco Muratore, Nicolò Pipitone, Carlo Salvarani

Research output: Contribution to journalArticlepeer-review


Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.

Original languageEnglish
Pages (from-to)e231-e239
JournalPresse medicale (Paris, France : 1983)
Issue number6
Publication statusPublished - Jun 1 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Biologics in vasculitides: Where do we stand, where do we go from now?'. Together they form a unique fingerprint.

Cite this